Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $15.00 at Citigroup

Sana Biotechnology (NASDAQ:SANA) had its price target increased by Citigroup from $8.00 to $15.00 in a research note released on Friday morning, Benzinga reports. Citigroup currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. HC Wainwright cut their target price on shares of Sana Biotechnology from $12.00 to $11.00 and set a buy rating on the stock in a research report on Friday. Rodman & Renshaw assumed coverage on Sana Biotechnology in a report on Wednesday, June 26th. They set a buy rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $14.25.

Sana Biotechnology Price Performance

NASDAQ:SANA traded up $0.25 during trading hours on Friday, hitting $4.91. The company’s stock had a trading volume of 2,261,241 shares, compared to its average volume of 1,825,041. The company has a market capitalization of $1.09 billion, a P/E ratio of -3.21 and a beta of 1.45. Sana Biotechnology has a twelve month low of $2.74 and a twelve month high of $12.00. The stock has a fifty day simple moving average of $5.90 and a 200-day simple moving average of $7.53.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). On average, equities analysts predict that Sana Biotechnology will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of SANA. Capital World Investors boosted its stake in Sana Biotechnology by 255.8% in the first quarter. Capital World Investors now owns 5,449,035 shares of the company’s stock worth $54,490,000 after buying an additional 3,917,728 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Sana Biotechnology by 24.1% during the 1st quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock valued at $121,552,000 after purchasing an additional 2,358,089 shares during the last quarter. PFM Health Sciences LP raised its position in Sana Biotechnology by 51.4% in the 4th quarter. PFM Health Sciences LP now owns 1,883,337 shares of the company’s stock worth $7,684,000 after purchasing an additional 639,198 shares during the period. Baillie Gifford & Co. raised its position in Sana Biotechnology by 5.0% in the 1st quarter. Baillie Gifford & Co. now owns 10,656,279 shares of the company’s stock worth $106,563,000 after purchasing an additional 506,262 shares during the period. Finally, Baker BROS. Advisors LP boosted its position in Sana Biotechnology by 19.0% during the first quarter. Baker BROS. Advisors LP now owns 2,380,949 shares of the company’s stock valued at $23,809,000 after buying an additional 380,949 shares during the period. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.